Neuroblastoma is a childhood tumour originating from the neural crest, for which treatment options are limited. Dyberg et al. report a high frequency of mutations in genes associated with RHO–RAC signalling in human neuroblastoma samples. Increased expression of the downstream RHO-activating kinase ROCK2 was associated with poor patient survival. In human neuroblastoma cell lines, ROCK2 inhibition promoted cell differentiation and decreased cell growth, migration and invasion. In mouse neuroblastoma models, the ROCK2 inhibitor HA1077 significantly suppressed tumour growth.
References
Dyberg, C. et al. Rho-associated kinase is a therapeutic target in neuroblastoma. Proc. Natl Acad. Sci. USA http://dx.doi.org/10.1073/pnas.1706011114 (2017).
Rights and permissions
About this article
Cite this article
Sarah, C. Inhibiting ROCK in neuroblastoma. Nat Rev Drug Discov 16, 602 (2017). https://doi.org/10.1038/nrd.2017.160
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.160
